Why Endocyte (ECYT) Stock Is Declining Today

NEW YORK (TheStreet) -- Endocyte (ECYT) shares are down 6.4% to $6.54 on Tuesday after Brean Capital downgraded the stock to "hold" from "buy".

The downgraded outlook stems from the firm's belief that the biotech company's investigational target cancer therapeutic treatment, Vintafolide, will only produce marginal returns for the company.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ECYT Chart ECYT data by YCharts
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts